A novel asexual blood-stage malaria vaccine candidate: PfRipr5 formulated with human-use adjuvants induces potent growth inhibitory antibodies

PfRipr is a highly conserved asexual-blood stage malaria vaccine candidate against . PfRipr5, a protein fragment of PfRipr inducing the most potent inhibitory antibodies, is a promising candidate for the development of next-generation malaria vaccines, requiring validation of its potential when form...

Full description

Saved in:

Bibliographic Details
Published in:	Frontiers in immunology Vol. 13; p. 1002430
Main Authors:	Takashima, Eizo, Nagaoka, Hikaru, Correia, Ricardo, Alves, Paula M, Roldão, António, Christensen, Dennis, Guderian, Jeffrey A, Fukushima, Akihisa, Viebig, Nicola K, Depraetere, Hilde, Tsuboi, Takafumi
Format:	Journal Article
Language:	English
Published:	Switzerland Frontiers Media S.A 27-10-2022
Subjects:	adjuvant Adjuvants, Immunologic Adjuvants, Pharmaceutic Alhydrogel Animals Antibodies, Protozoan Antigens, Protozoan asexual blood-stage malaria vaccine GLA-SE Humans Immunology Malaria Vaccines PfRipr5 Plasmodium falciparum Rabbits Plasmodium falciparum PfRipr5 asexual blood-stage malaria vaccine adjuvant Alhydrogel GLA-SE CAF01
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	PfRipr is a highly conserved asexual-blood stage malaria vaccine candidate against . PfRipr5, a protein fragment of PfRipr inducing the most potent inhibitory antibodies, is a promising candidate for the development of next-generation malaria vaccines, requiring validation of its potential when formulated with adjuvants already approved for human use. In this study, PfRipr5 antigen was efficiently produced in a tank bioreactor using insect High Five cells and the baculovirus expression vector system; purified PfRipr5 was thermally stable in its monomeric form, had high purity and binding capacity to functional monoclonal anti-PfRipr antibody. The formulation of purified PfRipr5 with Alhydrogel , GLA-SE or CAF 01 adjuvants accepted for human use showed acceptable compatibility. Rabbits immunized with these formulations induced comparable levels of anti-PfRipr5 antibodies, and significantly higher than the control group immunized with PfRipr5 alone. To investigate the efficacy of the antibodies, we used an parasite growth inhibition assay (GIA). The highest average GIA activity amongst all groups was attained with antibodies induced by immunization with PfRipr5 formulated with CAF 01. Overall, this study validates the potential of adjuvanted PfRipr5 as an asexual blood-stage malaria vaccine candidate, with PfRipr5/CAF 01 being a promising formulation for subsequent pre-clinical and clinical development.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Edited by: Abhay Satoskar, The Ohio State University, United States This article was submitted to Parasite Immunology, a section of the journal Frontiers in Immunology Reviewed by: Ashley Vaughan, Seattle Children’s Research Institute, United States; Bright Adu, University of Ghana, Ghana
ISSN:	1664-3224 1664-3224
DOI:	10.3389/fimmu.2022.1002430